In late July 2020, the US Food and Drug Administration (FDA) granted accelerated approval to brexucabtagene autoleucel (KTE-X19) for treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). MCL is a rare, aggressive form of non-Hodgkin lymphoma (NHL) that originates in the mantle zone of the lymph node. Brexucabtagene autoleucel, manufactured by […]

In the past, many pharma companies followed the same brand planning playbook. These strategies emphasized in-person events and traditional sales strategies, but the pharma market is shifting. In a post–COVID-19 world, live conferences and sales events are out. Healthcare providers (HCPs) are looking for different forms of engagement and leaning toward virtual contacts. More than […]

The COVID-19 pandemic has presented challenges both to the medical system overall and to the ongoing treatment of patients with cancer. Patients are experiencing delays in care, additional financial strains, and mental health challenges in the current environment. To measure the impact of the COVID-19 pandemic on cancer patients, the American Cancer Society Cancer Action […]

With the continued increase of COVID-19 cases in the United States, social distancing guidelines remain crucial for combating the disease and limiting its spread. Cancer patients remain a highly vulnerable population that must balance social distancing guidelines with receiving necessary treatment in clinics. Following recent results from the FeDeriCa study, the US Food and Drug […]